SLShudong Liu

Shudong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shudong Liu has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute fluoroacetamide poisoning with reversible leukoencephalopathy: A case report and literature review highlighting the effectiveness of acetamide and the diagnostic value of neuroimaging

    by Zhongliang Mm Xu, Shaopeng Mm Ma, Zhuangfei Bs Li, Shengkun Bs Yang, Deyu Yang, Zhengze Mm Shen, Shudong Liu

    Rationale: Acute fluoroacetamide poisoning is a rare and life-threatening emergency. Diagnosis is challenging due to nonspecific symptoms and a latent period. This report emphasizes the effectiveness of delayed acetamide treatment and the importance of neuroimaging for diagnosis and monitoring. Patient concerns: A 58-year-old man was admitted to the emergency room about 5 hours after intentionally ingesting an unknown pesticide following a personal conflict. Diagnoses: Fluoroacetamide poisoning was initially suspected based on prior domestic case reports, the patient history of pesticide ingestion, clinical signs, and diffusion-weighted magnetic resonance imaging (MRI) showing characteristic features of cytotoxic edema in specific brain regions. Upon confirming the pesticide product with the seller, the diagnosis was ultimately confirmed as fluoroacetamide poisoning. Interventions: Gastric lavage, intramuscular acetamide, fluid resuscitation, and electrolyte correction were administered. Outcomes: The patient showed rapid clinical improvement after receiving acetamide. He was discharged after one week without any additional medication. Follow-up MRI at one month showed complete resolution of the previous abnormalities, and he reported no symptoms at the one-year follow-up. Lessons: This case highlights the potential advantages of delaying acetamide treatment and suggests that brain diffusion-weighted MRI could be valuable in diagnosing and monitoring acute fluoroacetamide poisoning.

  • Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial

    by Xiaochuan Huo, Dapeng Sun, Thanh N. Nguyen, Gaoting Ma, Yuesong Pan, Xin Tong, Guangxiong Yuan, Hongxing Han, Wenhuo Chen, Ming Wei, et al.

    BACKGROUND: Several trials have shown the benefit and safety of endovascular therapy (EVT) compared with medical management (MM) of patients with a large ischemic core in the 90-day follow-up. However, the 1-year outcome comparison between EVT and MM in Asian patients with a large ischemic core has not been investigated. Our aim was to evaluate the 1-year outcomes of patients in the ANGEL-ASPECT trial (Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core). METHODS: In this phase 3, randomized, open-label, blinded end point assessment trial, patients with anterior circulation large vessel occlusion and an Alberta Stroke Program Early CT Score of 3 to 5 or an infarct core volume of 70 to 100 mL were enrolled across 46 hospitals in China. Patients were randomly assigned 1:1 to EVT or MM. The 90-day outcomes were previously reported. We report a prespecified analysis of the ANGEL-ASPECT trial, with 1-year functional outcome as the primary outcome in this study. The primary outcome was the shift of the modified Rankin Scale (mRS) score (range, 0–6, with a higher score reflecting greater disability) to better outcomes at 1-year. The secondary outcomes included functional independence (mRS score, 0–2), independent ambulation (mRS score, 0–3), and mortality. This trial is registered with https://www.clinicaltrials.gov (Unique identifier: NCT04551664). RESULTS: One-year data were available for 425 of 455 (93%) patients for the primary outcome, with 214 patients in the EVT group and 211 in the MM group in the complete case analysis. The mean age was 66 years, and 38.1% were female. There was a greater likelihood of shift toward improved 1-year mRS distribution in the EVT compared with the MM group (generalized odds ratio, 1.25 [95% CI, 1.01–1.56]; P =0.04). Functional independence and independent ambulation were higher in the EVT compared with MM groups (mRS score, 0–2: 30.4% [65/214] versus 17.1% [36/211]; relative risk, 1.87 [95% CI, 1.27–2.75]; mRS score, 0–3: 50.0% [107/214] versus 35.6% [75/211]; relative risk, 1.46 [95% CI, 1.15–1.85], respectively). The 1-year mortality rate was 31.3% (67/214) in the EVT group and 26.5% (56/211) in the MM group (relative risk, 1.12 [95% CI, 0.82–1.53]). In addition, no change was found in the rate of functional independence between 90 days and 1 year in the EVT group (29.4% [69/214] versus 30.4% [65/214], respectively); however, a gain in functional independence was observed in the MM group from 90 days to 1 year (10.9% [26/211] versus 17.1% [36/211]), narrowing the magnitude of EVT treatment effect from 18.5% at 90 days to 13.3% at 1 year. CONCLUSIONS: In patients with large ischemic stroke from a proximal arterial occlusion presenting within 24 hours of onset, EVT reduced disability with durable 1-year benefit compared with MM. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.


  • Open Access

    Patchy profile sign in RAPID software: a specific marker for intracranial atherosclerotic stenosis in acute ischemic stroke

    by Lingwen Zhang, Hua Xue, Xiaoqing Bu, Juan Liao, Ge Tang, Yu Chen, Libo Zhao, Deyu Yang, Li Liu, Shudong Liu

    Purpose: Identifying the etiology of acute ischemic stroke (AIS) before endovascular treatment (EVT) is important but challenging. In CT perfusion imaging processed by perfusion software, we observed a phenomenon called patchy profile sign (PPS), that is, the hypoperfusion morphology in RAPID software is a discontinuous sheet pattern. This phenomenon is predominantly observed in patients diagnosed with intracranial atherosclerotic stenosis (ICAS). The study intends to assess whether the PPS can be used to differentiate ICAS from intracranial embolism.Method: Patients with AIS due to M1 segment occlusion of the MCA who underwent mechanical thrombectomy were retrospectively enrolled. The receiver operating characteristic (ROC) curve analysis was performed to assess the value of PPS in predicting ICAS. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the PPS for prediction of ICAS were calculated.Results: A total of 51 patients were included in the study. The PPS was observed in 10 of 19 (52.6%) patients with ICAS, and in 2 of 32 (6.3%) patients with intracranial embolism (p < 0.001). Interobserver agreement for identifying PPS was excellent (κ = 0.944). The sensitivity, specificity, PPV, NPV, and accuracy of the PPS for predicting ICAS were 52.6, 93.8, 83.3, 76.9, and 78.4%, respectively.Conclusion: The PPS on RAPID software is an imaging marker with high specificity for ICAS. Larger sample sizes are imperative to validate the findings.

  • Intravenous Tirofiban Versus Alteplase Before Endovascular Treatment in Acute Ischemic Stroke: A Pooled Analysis of the DEVT and RESCUE BT Trials

    by Hongfei Sang, Zhihua Cao, Jie Du, Thanh N. Nguyen, Jeffrey L. Saver, An Mao, Raul G. Nogueira, Zhaojun Tao, Simin Zhou, Qin Han, et al.

    BACKGROUND: The present study aimed to evaluate the efficacy and safety of intravenous tirofiban versus alteplase before endovascular treatment (EVT) in acute ischemic stroke patients with intracranial large vessel occlusion. METHODS: This was a post hoc analysis using data from 2 multicenter, randomized trials: the DEVT trial (Direct Endovascular Treatment for Large Vessel Occlusion Stroke) from May 2018 to May 2020 and the RESCUE BT trial (Intravenous Tirofiban Before Endovascular Thrombectomy for Acute Ischemic Stroke) from October 2018 to October 2021. Patients with acute intracranial large vessel occlusion within 4.5 hours from last known well were dichotomized into 2 groups: tirofiban plus EVT versus alteplase bridging with EVT. The primary outcome was functional independence (modified Rankin Scale score of 0–2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage and 3-month mortality. Multivariable logistic regression (adjusting for baseline systolic blood pressure, occlusion site, onset-to-puncture time, anesthesia, and first choice of EVT) and propensity score overlap weighting (balance in demographic covariates, stroke characteristics, and initial management between groups) were performed. RESULTS: One-hundred and eighteen alteplase-treated patients in the DEVT trial and 98 tirofiban-treated patients in the RESCUE BT trial were included (median age, 70 years; 115 [53.2%] men). The rate of functional independence was 60.2% in the tirofiban group compared with 46.6% in the alteplase group (adjusted odds ratio, 1.25 [95% CI, 0.60–2.63]). Compared with alteplase, tirofiban was not associated with increased risk of symptomatic intracranial hemorrhage (6.8% versus 9.2%; P =0.51) and mortality (17.8% versus 19.4%; P =0.76). The propensity score overlap weighting analyses showed consistent outcomes. CONCLUSIONS: Among patients with intracranial large vessel occlusion within 4.5 hours of onset, tirofiban plus EVT was comparable to alteplase bridging with EVT regarding the efficacy and safety outcomes. These findings should be interpreted as preliminary and require confirmation in a randomized trial. REGISTRATION: URL: https://www.chictr.org.cn ; Unique identifiers: ChiCTR-IOR-17013568 and ChiCTR-INR-17014167.


  • Open Access

    Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry

    by Huagang Li, Dongsheng Ju, Zhaojun Tao, Jiayin Wang, Thanh N. Nguyen, Jeffrey L. Saver, Raul G. Nogueira, Chang Liu, Qingwu Yang, Zhongming Qiu, et al.

    Background: Approximately half of patients who achieve successful reperfusion do not achieve functional independence. The present study sought to investigate the clinical outcomes and safety of intraarterial or intravenous tirofiban as adjunct therapy in patients with acute basilar artery occlusion who had achieved successful recanalization with endovascular treatment. Methods and Results: In the national, prospective BASILAR (Endovascular Treatment for Acute Basilar Artery Occlusion Study) registry, 458 patients who met inclusion criteria were divided into 3 groups based on tirofiban administration (no tirofiban, n=262; intravenous tirofiban, n=101; intraarterial+intravenous tirofiban, n=95). Their clinical outcomes were compared with 90‐day modified Rankin Scale scores. Adjusted odds ratios (aORs) and 95% CIs were obtained by logistic regression models and propensity score matching. Safety outcomes included any intracranial hemorrhage (ICH), symptomatic ICH, and mortality. Among 458 included patients, 184 (40.2%) achieved a favorable outcome (modified Rankin Scale score 0–3). There were no differences between the intravenous tirofiban group and the no tirofiban group in terms of safety and clinical outcomes (all P >0.05). Compared with the no tirofiban group, the intraarterial+intravenous tirofiban group had higher odds of 90‐day modified Rankin Scale score 0 to 3 (aOR, 2.44 [95% CI, 1.30–4.64], P =0.006) and lower 3‐month mortality (aOR, 0.38 [95% CI, 0.19–0.71], P =0.002) without an increase in any ICH (aOR, 0.34 [95% CI, 0.09–1.01], P =0.07) or symptomatic ICH (aOR, 0.23 [95% CI, 0.03–0.90], P =0.05). Similar results of intraarterial+intravenous tirofiban on improving clinical outcomes were detected in novel cohorts constructed by propensity score matching. Conclusions: Intraarterial+intravenous rather than intravenous tirofiban improved clinical outcomes without increasing the frequency of symptomatic ICH among patients with basilar artery occlusion after successful endovascular treatment. Further studies are needed to delineate the roles of intraarterial+intravenous tirofiban in patients with basilar artery occlusion receiving endovascular treatment.


  • Risk score for symptomatic intracranial haemorrhage in patients with acute ischaemic stroke receiving endovascular treatment

    by Jian Zhang, Juan Liu, Shijian Chen, Huagang Li, Jun Luo, Youlin Wu, Peiyang Zhou, Wenguo Huang, Yue Wan, Tao Qiu, et al.


  • Open Access

    The Natural History and Reperfusion Therapy Outcomes of Acute Ischemic Stroke due to Isolated M2 Occlusions

    by Hongmin Gong, Libo Zhao, Ge Tang, Yu Chen, Deyu Yang, Shudong Liu

    Objective. Currently, the standard treatment modality for patients with acute ischemic stroke (AIS) presenting with isolated M2 occlusions is not specific. We therefore assessed the difference in treatment outcomes for patients with isolated M2 occlusions. Methods. We retrospectively analyzed consecutive patients with AIS presenting with isolated M2 occlusions from October 1, 2018, to June 30, 2020. Patients were divided into 3 groups based on the treatments they received: no reperfusion therapy (NRT), intravenous thrombolysis treatment (IVT), and endovascular intervention (EVT), which comprised IVT in conjunction with EVT or EVT alone. The primary outcomes were improvements in modified Rankin Scale (mRS) scores at 90 days and National Institutes of Health Stroke Scale (NIHSS) scores at 24 hours after treatment compared with the baseline. The secondary efficacy outcome comprised a good outcome rate defined as a 90 − day mRS score ≤ 2, final infarct volume (FIV), 90‐day mortality rate, and successful recanalization rate, which was defined as a modified thrombolysis in cerebral infarction score ≥ 2b. Safety outcomes included symptomatic intracerebral hemorrhage and procedure‐related complications. Results. Seventy patients were enrolled and divided into 3 groups: the NRT group (n = 25), IVT group (n = 27), and EVT group (n = 18). Twenty‐four‐hour posttreatment NIHSS scores were substantially decreased by EVT compared with NRT (adjusted β ‐4.01, 95% confidence interval [CI] ‐6.60 to ‐1.43; P = 0.003) or IVT (adjusted β, ‐3.61 [95% CI, ‐6.45 to ‐0.77]; P = 0.013). Compared with the outcomes observed after NRT, patients who received EVT were more likely to achieve lower 90‐day mRS scores (adjusted β, ‐1.42 [95% CI, ‐2.66 to ‐0.63]; P = 0.007), higher good outcome rates (adjusted odds ratio, 8.73 [95% CI, 1.43‐53.24]; P = 0.019), and smaller FIVs (adjusted β, ‐29.66 [95% CI, ‐59.73 to 0.42]; P = 0.048). The recanalization rate of EVT was high (88.89%), and procedure‐related complications were rare (5.56%). Conclusions. For acute, isolated M2 occlusions, EVT could dramatically and rapidly improve neurological deficits with high safety and effectiveness. These changes were observed at 24 hours after treatment and were maintained over the long term.